ArticleExperimental and therapeutic medicine2018
Abnormal expression of miR-4784 in chondrocytes of osteoarthritis and associations with chondrocyte hyperplasia.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Epigenetic Regulation of Chondrocytes and Subchondral Bone in Osteoarthritis.Life (Basel, Switzerland) · 2022Review
- Recent Advances in Pharmacological Intervention of Osteoarthritis: A Biological Aspect.Frontiers in pharmacology · 2021Review
- Role of MicroRNA, LncRNA, and Exosomes in the Progression of Osteoarthritis: A Review of Recent Literature.Orthopaedic surgery · 2020Review
- LINC01133 promotes the progression of cervical cancer by sponging miR-4784 to up-regulate AHDC1.Cancer biology & therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to assess the expression of microRNA (miRNA)-4784 in the chondrocytes of early osteoarthritis (OA) and to determine the effect of double-stranded (ds)-miRNA-4784 transfection on chondrocyte function. Following the construction of an OA rabbit model, normal chondrocytes (normal control group), OA chondrocytes obtained 4 weeks after modeling (OA at week 4 group) and 8 weeks after modeling (OA at week 8 group) were used. The relative expression of miRNA-4784 in each group was detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Western blotting was performed to measure the expression of type II collagen (Col2a1) and matrix metalloproteinase (MMP)-3 in each group with or without ds-miRNA-4784 transfection. The results revealed that the levels of miR-4784 in groups OA at week 4 and 8 were significantly lower than that of normal control group (P<0.05). It was also demonstrated that Col2a1 mRNA expression levels in groups OA at week 4 and 8 were 49 and 38% of that in the normal control group, respectively. Furthermore, MMP-3 mRNA expression levels increased by 3.12- and 3.95-fold in groups OA at week 4 and 8, respectively, compared with those in the normal control group (P<0.01). Following transfection with ds-miRNA-4784, Col2a1 mRNA expression levels increased by 63 and 126% compared with the levels prior to treatment in groups OA at week 4 and 8, respectively (P<0.01). The expression levels of MMP-3 mRNA in groups OA at week 4 and 8 decreased following transfection compared with the levels prior to treatment. Col2a1 and MMP-3 protein expression exhibited similar patterns to the mRNA expression. In summary, the results of the present study suggest that miRNA-4784 expression is significantly reduced in early stage OA chondrocytes. Transfection with ds-miRNA-4784 promotes the expression of Col2a1 and inhibits the MMP-3 expression in chondrocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.